Company Encyclopedia
View More
name
Pyxis Oncology
PYXS.US
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc.
1.912 T
PYXS.USMarket value -Rank by Market Cap -/-

Financial Score

20/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking283/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-87.28%E
    • Profit Margin-3442.77%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-82.53%E
    • Net Profit YoY-69.27%E
    • Total Assets YoY-45.93%E
    • Net Assets YoY-55.25%E
  • Cash ScoreE
    • Cash Flow Margin-2.90%D
    • OCF YoY-82.53%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreB
    • Gearing Ratio34.87%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Analysts Sound Alarm On Pyxis Oncology's Tiny Trial

    Analysts express concerns over Pyxis Oncology's Phase 1 trial data for MICVO, citing limited data interpretability and high discontinuation rates. Despite promising response rates, the small sample size adds uncertainty. Pyxis shares fell 49% due to these concerns, with analysts reiterating a Market Perform rating. The company plans to present updated data in 2026 and has secured $11 million in non-dilutive funding to support MICVO's development.

    benzinga_article·
    US
    PYXS
    -26.30%
    benzinga_article·
    US
    PYXS
    -26.30%

    Stifel Nicolaus Sticks to Its Buy Rating for Pyxis Oncology (PYXS)

    Stifel Nicolaus analyst Stephen Willey maintained a Buy rating for Pyxis Oncology with a $9.00 price target. Willey, a 4-star analyst on TipRanks, focuses on the Healthcare sector. LifeSci Capital's Sam Slutsky also issued a Buy rating, while William Blair reiterated a Hold rating for Pyxis Oncology.

    Tip Ranks·
    US
    PYXS
    -26.30%
    Tip Ranks·
    US
    PYXS
    -26.30%

    12 Health Care Stocks Moving In Thursday's Intraday Session

    During Thursday's intraday session, several healthcare stocks experienced significant price movements. Notable gainers included Athira Pharma, which rose 70% to $7.03, and Canopy Growth, up 19.75% to $2.3. On the losing side, Pyxis Oncology fell 46.6% to $1.8, and Werewolf Therapeutics decreased by 39.25% to $0.65. These fluctuations reflect the dynamic nature of the healthcare stock market.

    benzinga_article·
    US
    PYXS
    -26.30%
    US
    HOWL
    +6.22%
    US
    ATHA
    +3.72%
    benzinga_article·
    US
    PYXS
    -26.30%
    US
    HOWL
    +6.22%
    US
    ATHA
    +3.72%

    U.S. Stock Market Midday Update: Pyxis Oncology's clinical trial results fall short of expectations, causing stock price to plummet 53.16%, triggering market turbulence

    Pyxis Oncology fell 53.16%; Insmed fell 14.67%, with a transaction volume of USD 198 million; Amgen fell 0.29%, with a transaction volume of USD 7.66 million; AbbVie rose 0.18%, with a transaction volume of USD 5.332 million; Gilead Sciences fell 0.04%, with a market capitalization of USD 150.5 billion

    Tracking Unusual Activity·
    US
    PYXS
    -26.30%
    Tracking Unusual Activity·
    US
    PYXS
    -26.30%

    Pyxis Oncology shares are trading lower. The company announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin.

    benzinga_article·
    US
    PYXS
    -26.30%
    benzinga_article·
    US
    PYXS
    -26.30%
    © 2025 Longbridge｜Disclaimer